Xencor has been granted a patent for novel antibodies that bind to Prostate Specific Membrane Antigen (PSMA) and CD3, potentially aiding in the treatment of PSMA-related cancers. The patent includes a detailed claim outlining the structure of a heterodimeric antibody for this purpose. GlobalData’s report on Xencor gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Xencor Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Xencor, Personalized cancer vaccines was a key innovation area identified from patents. Xencor's grant share as of February 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

Heterodimeric antibody binding psma and cd3 for cancer treatment

Source: United States Patent and Trademark Office (USPTO). Credit: Xencor Inc

A recently granted patent (Publication Number: US11919956B2) discloses a heterodimeric antibody comprising two monomers, each with specific variable heavy and light domains forming PSMA binding domains. The first monomer includes a VH1-CH1-linker 1-scFv-linker 2-CH2-CH3 structure, while the second monomer consists of a VH2-CH1-hinge-CH2-CH3 configuration. Both monomers share a common light chain with variable light domains. The amino acid sequences of the variable heavy and light domains are specified in the claims, ensuring the unique composition and binding properties of the antibody.

Furthermore, the patent details the nucleic acid composition and expression vector composition necessary for producing the heterodimeric antibody. The nucleic acid composition includes three nucleic acids encoding the first and second monomers, along with the common light chains. These nucleic acids are incorporated into expression vectors, each in a separate vector, to facilitate the expression of the antibody. Finally, the patent covers the transformation of host cells with the expression vector composition, enabling the production of the heterodimeric antibody. Overall, the patent provides a comprehensive disclosure of the antibody structure, nucleic acid sequences, and expression vector systems required for its production, emphasizing the novelty and utility of the invention in the field of antibody therapeutics.

To know more about GlobalData’s detailed insights on Xencor, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies